A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels

A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels

Background: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials. However, less is known about the efficacy of PCSK9 inhibition in clinical p...

Full description

Bibliographic Details
Main Authors: Maria K. Svensson, Stefan James, Annica Ravn-Fischer, Guillermo Villa, Lovisa Schalin, Thomas Cars, Stefan Gustafsson, Emil Hagström
Format: Article
Language:English
Published: Upsala Medical Society 2024-01-01
Series:Upsala Journal of Medical Sciences
Subjects:
adherence
evolocumab
ldl-c
pcsk9 inhibitors
persistence
real-world evidence
Online Access:https://ujms.net/index.php/ujms/article/view/9618/16831

Internet

https://ujms.net/index.php/ujms/article/view/9618/16831

Similar Items